Mylan Adds to Growing Women's Healthcare Portfolio with Launch of Generic for Oral Contraceptive Yaz® Read More »

Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home Read More »

Shire announces revised proposal and extension of PUSU deadline to 8 May 2018 The Board of Shire (the “Board”) announced earlier today that it had received a further revised proposal from Takeda Pharmaceutical Company Limited (“Takeda”) regarding a possible offer for the Company. Read More »

AstraZeneca and MedImmune, its global biologics research and development arm, today announced high-level results from the Phase III ARCTIC trial in patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least two prior treatments. Read More »

Shire notes the announcement made by Takeda. The Board of Shire (the “Board”) confirms that it has received three conditional proposals from Takeda regarding a possible offer for the Company, on 29 March 2018 (the “First Proposal”), 11 April 2018 (the “Second Proposal”) and 13 April 2018 (the “Third Proposal”). Read More »

Merck known as MSD outside the United States and Canada, announced that following validation by the European Medicines Agency (EMA), the centralized review process has begun for the company’s Type II Variation, which seeks approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with pemetrexed (ALIMTA®) and platinum chemotherapy (cisplatin or carboplatin) for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC). Read More »

Astellas Pharma Inc. announced that it submitted on March 23, 2018, a new drug application (NDA) for marketing approval of gilteritinib (generic name) in Japan for the treatment of adult patients with FLT3 mutation-positive (FLT3mut+) relapsed or refractory acute myeloid leukemia (AML). Read More »

Merck known as MSD outside the United States and Canada, announced that a pivotal Phase 3 study of relebactam, the company’s investigational beta-lactamase inhibitor, in combination with imipenem/cilastatin, demonstrated a favorable overall response in the treatment of certain imipenem–non-susceptible bacterial infections, the primary endpoint, with lower treatment-emergent nephrotoxicity (kidney toxicity), a secondary endpoint, compared to a Colistin (colistimethate sodium) plus imipenem regimen. Read More »

Pfizer Inc. announced that TRUMENBA® (Meningococcal Group B Vaccine) received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for active immunization to prevent invasive disease caused by Neisseria meningitidis group B (MenB) in children ages 1 through 9 years. Read More »

Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has dosed the first patient in the Company’s Phase 1/2 clinical trial evaluating the safety and efficacy of an investigational AAV-based gene therapy for the treatment of X-linked retinitis pigmentosa (XLRP). Read More »

Merck known as MSD outside the United States and Canada, and Invenergy, North America’s largest privately held renewable energy company, announced a Virtual Power Purchase Agreement (VPPA) that adds 60 megawatts (MW) of renewable energy to the electrical grid and supports Merck’s environmental sustainability goals. Read More »

Mylan Presents Equivalence Data on Glatiramer Acetate Compared to Copaxone® at American Academy of Neurology 70th Annual Meeting Read More »

Mallinckrodt Pharmaceuticals , a leading global specialty pharmaceutical company, will present on Tuesday, May 22, 2018, at the UBS Global Healthcare Conference at the Grand Hyatt New York, 109 East 42nd St., New York. Read More »

The Board of Directors of McKesson today released its response to a request from the International Brotherhood of Teamsters, a McKesson stockholder, that the Board perform an investigation into senior management’s and the Board’s oversight of McKesson’s compliance with its legal and regulatory obligations relating to the distribution of opioids. Read More »

Mallinckrodt plc a leading global specialty pharmaceutical company, announced the $300 million repayment of unsecured, fixed-rate notes maturing April 15, 2018 with cash on hand. Read More »

Amgen announced that it will report its first quarter 2018 financial results on Tuesday, April 24, 2018, after the close of the U.S. financial markets. Read More »

Aetna’s recently announced expansion efforts in Wellesley, Mass., not only demonstrate the company’s commitment to the local community, but to transforming the consumer health experience. Read More »

Amarin Corporation plc a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular (CV) health, announced that Aaron Berg has been promoted to the position of Senior Vice President, Chief Commercial Officer. Read More »

The nominating committees for the ASHP Pharmacy Practice Sections recently approved candidates for Executive Committee Chairs and Directors-at-Large. Read More »

The ASHP Committee on Nominations met on April 19 and approved the following ASHP members as candidates for ASHP elected offices: Read More »